Nonacog beta pegol
- Generic Name
- Nonacog beta pegol
- Brand Names
- Refixia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1175512-71-6
- Unique Ingredient Identifier
- 27Y83O992Q
- Background
Nonacog beta pegol is a recombinant coagulation factor IX derivative. It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation. Once activated, the activation molecule with PEG is cleaved to leave the activated factor IX (Factor IXa). Nonacog beta pegol was developed by Novo Nordisk and received its first global approval by the FDA on May 31, 2017, followed by the European Commission approval on June 2, 2017. Nonacog beta pegol was approved by Health Canada on November 29, 2017.
- Indication
Nonacog beta pegol is indicated in adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease) for control and prevention of bleeding episodes as well as control and prevention of bleeding in the perioperative setting. It is also used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
- Associated Conditions
- Bleeding caused by Hemophilia B
- Associated Therapies
- Perioperative management therapy
Hemophilia B Clinical Trials 2024: EMA, PDMA, FDA Approvals
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.